Krystal Biotech, Inc. (KRYS): Price and Financial Metrics
GET POWR RATINGS... FREE!
KRYS Stock Price Chart Interactive Chart >
KRYS Price/Volume Stats
|Current price||$74.72||52-week high||$102.99|
|Prev. close||$74.73||52-week low||$38.86|
|Day high||$75.60||Avg. volume||204,904|
|50-day MA||$60.35||Dividend yield||N/A|
|200-day MA||$60.92||Market Cap||1.92B|
Krystal Biotech, Inc. (KRYS) Company Bio
Krystal Biotech Inc. develops and commercializes pharmaceutical products for patients suffering from dermatological diseases. The company’s lead product candidate includes KB103, which is in preclinical studies to treat dystrophic epidermolysis bullosa, a genetic disease. The company was founded in 2015 and is based in Pittsburgh, Pennsylvania.
Most Popular Stories View All
KRYS Latest News Stream
|Loading, please wait...|
KRYS Latest Social Stream
View Full KRYS Social Stream
Latest KRYS News From Around the Web
Below are the latest news stories about Krystal Biotech Inc that investors may wish to consider to help them evaluate KRYS as an investment opportunity.
PITTSBURGH, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat at Cowen’s 42nd Annual Health Care Conference, which is taking place virtually March 7-9, 2022. Details are as follows: Fireside Chat Date:Monday, March 7, 2022Fireside Chat Time:2:50-3:20 p.m. ESTWebcast link:https://wsw.com/webcast/cowen108/krys/2056
During the last session, Krystal Biotech Inc. (NASDAQ:KRYS)s traded shares were 0.3 million, with the beta value of the company hitting 0.99. At the end of the trading day, the stocks price was $60.86, reflecting an intraday loss of -6.84% or -$4.47. The 52-week high for the KRYS share is $102.99, that puts it down Is Krystal Biotech Inc. (NASDAQ: KRYS) Still A Loss Stock Despite Being Down -12.99% YTD? Read More »
Investment company Act Capital Management, Llc (Current Portfolio) buys Adtran Inc, Meta Platforms Inc, Vir Biotechnology Inc, AirSculpt Technologies Inc, enVVeno Medical Corp, sells , Upstart Holdings Inc, Affirm Holdings Inc, Nektar Therapeutics, Nuance Communications Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Act Capital Management, Llc.
Investing in small-cap, clinical-stage biotech stocks can be a double-edged sword. With that in mind, let's turn to two biotech stocks that could soar (and provide above-average returns to patient investors): Krystal Biotech (NASDAQ: KRYS) and Editas Medicine (NASDAQ: EDIT). Krystal Biotech develops gene-editing therapies for rare skin diseases.
Krystal Biotech Inc (NASDAQ: KRYS ) shares have potential to nearly double from current levels, according to an analyst at BofA Securities. The Krystal Biotech Analyst: Geoff Meacham initiated coverage of Krystal Biotech shares with a Buy rating and a $110 price target. The Krystal Biotech Thesis: Krystal Biotech, a clinical-stage biotech, is developing differentiated HSV-based gene therapies for inherited dermatological and respiratory diseases, Meacham said in a note. Krystal differentiates itself due to its ability to package large transgenes and re-dose their gene therapies in a transient manner, which significantly increases the breadth of potential applications, the analyst said. Nominated therapeutic areas include cystic fibrosis, Full story available on Benzinga.com
KRYS Price Returns